These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

237 related items for PubMed ID: 30554531

  • 1. Treatment of moderate to severe dyspareunia with intravaginal prasterone therapy: a review.
    Portman DJ, Goldstein SR, Kagan R.
    Climacteric; 2019 Feb; 22(1):65-72. PubMed ID: 30554531
    [Abstract] [Full Text] [Related]

  • 2. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause.
    Labrie F, Archer DF, Koltun W, Vachon A, Young D, Frenette L, Portman D, Montesino M, Côté I, Parent J, Lavoie L, BSc AB, Martel C, Vaillancourt M, Balser J, Moyneur É, members of the VVA Prasterone Research Group.
    Menopause; 2018 Nov; 25(11):1339-1353. PubMed ID: 30358731
    [Abstract] [Full Text] [Related]

  • 3. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause.
    Labrie F, Archer DF, Koltun W, Vachon A, Young D, Frenette L, Portman D, Montesino M, Côté I, Parent J, Lavoie L, Beauregard A, Martel C, Vaillancourt M, Balser J, Moyneur É, VVA Prasterone Research Group.
    Menopause; 2016 Mar; 23(3):243-56. PubMed ID: 26731686
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Prasterone: A Review in Vulvovaginal Atrophy.
    Heo YA.
    Drugs Aging; 2019 Aug; 36(8):781-788. PubMed ID: 31290076
    [Abstract] [Full Text] [Related]

  • 6. An overview of dehydroepiandrosterone (EM-760) as a treatment option for genitourinary syndrome of menopause.
    Holton M, Thorne C, Goldstein AT.
    Expert Opin Pharmacother; 2020 Mar; 21(4):409-415. PubMed ID: 31928093
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Lack of influence of dyspareunia on the beneficial effect of intravaginal prasterone (dehydroepiandrosterone, DHEA) on sexual dysfunction in postmenopausal women.
    Labrie F, Archer D, Bouchard C, Fortier M, Cusan L, Gomez JL, Girard G, Baron M, Ayotte N, Moreau M, Dubé R, Côté I, Labrie C, Lavoie L, Gilbert L, Martel C, Balser J.
    J Sex Med; 2014 Jul; 11(7):1766-85. PubMed ID: 24774442
    [Abstract] [Full Text] [Related]

  • 10. Combined data of intravaginal prasterone against vulvovaginal atrophy of menopause.
    Labrie F, Archer DF, Martel C, Vaillancourt M, Montesino M.
    Menopause; 2017 Nov; 24(11):1246-1256. PubMed ID: 28640161
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Evaluation of the acceptability of intravaginal prasterone ovule administration using an applicator.
    Montesino M, Labrie F, Archer DF, Zerhouni J, Côté I, Lavoie L, Beauregard A, Martel C, Vaillancourt M, Moyneur E, Balser J.
    Gynecol Endocrinol; 2016 Nov; 32(3):240-5. PubMed ID: 26634942
    [Abstract] [Full Text] [Related]

  • 14. Intravaginal dehydroepiandrosterone (Prasterone), a physiological and highly efficient treatment of vaginal atrophy.
    Labrie F, Archer D, Bouchard C, Fortier M, Cusan L, Gomez JL, Girard G, Baron M, Ayotte N, Moreau M, Dubé R, Côté I, Labrie C, Lavoie L, Berger L, Gilbert L, Martel C, Balser J.
    Menopause; 2009 Nov; 16(5):907-22. PubMed ID: 19436225
    [Abstract] [Full Text] [Related]

  • 15. Intravaginal dehydroepiandrosterone (prasterone), a highly efficient treatment of dyspareunia.
    Labrie F, Archer DF, Bouchard C, Fortier M, Cusan L, Gomez JL, Girard G, Baron M, Ayotte N, Moreau M, Dubé R, Côté I, Labrie C, Lavoie L, Berger L, Gilbert L, Martel C, Balser J.
    Climacteric; 2011 Apr; 14(2):282-8. PubMed ID: 21244215
    [Abstract] [Full Text] [Related]

  • 16. Prasterone has parallel beneficial effects on the main symptoms of vulvovaginal atrophy: 52-week open-label study.
    Labrie F, Archer DF, Bouchard C, Girard G, Ayotte N, Gallagher JC, Cusan L, Baron M, Blouin F, Waldbaum AS, Koltun W, Portman DJ, Côté I, Lavoie L, Beauregard A, Labrie C, Martel C, Balser J, Moyneur É, Members of the VVA Prasterone Group.
    Maturitas; 2015 May; 81(1):46-56. PubMed ID: 25771041
    [Abstract] [Full Text] [Related]

  • 17. Serum steroid concentrations remain within normal postmenopausal values in women receiving daily 6.5mg intravaginal prasterone for 12 weeks.
    Martel C, Labrie F, Archer DF, Ke Y, Gonthier R, Simard JN, Lavoie L, Vaillancourt M, Montesino M, Balser J, Moyneur É, other participating members of the Prasterone Clinical Research Group.
    J Steroid Biochem Mol Biol; 2016 May; 159():142-53. PubMed ID: 26972555
    [Abstract] [Full Text] [Related]

  • 18. The vagina as source and target of androgens: implications for treatment of GSM/VVA, including DHEA.
    Cipriani S, Maseroli E, Ravelli SA, Vignozzi L.
    Climacteric; 2023 Aug; 26(4):309-315. PubMed ID: 37288964
    [Abstract] [Full Text] [Related]

  • 19. Estradiol vaginal inserts (4 µg and 10 µg) for treating moderate to severe vulvar and vaginal atrophy: a review of phase 3 safety, efficacy and pharmacokinetic data.
    Constantine GD, Simon JA, Pickar JH, Archer DF, Bernick B, Graham S, Mirkin S.
    Curr Med Res Opin; 2018 Dec; 34(12):2131-2136. PubMed ID: 30238814
    [Abstract] [Full Text] [Related]

  • 20. Serum levels of sex steroids and metabolites following 12 weeks of intravaginal 0.50% DHEA administration.
    Ke Y, Labrie F, Gonthier R, Simard JN, Bergeron D, Martel C, Vaillancourt M, Montesino M, Lavoie L, Archer DF, Balser J, Moyneur E, other participating Members of the Prasterone Clinical Research Group.
    J Steroid Biochem Mol Biol; 2015 Nov; 154():186-96. PubMed ID: 26291918
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.